Corcept Therapeutics (CORT) Accumulated Expenses (2010 - 2026)

Corcept Therapeutics has disclosed Accumulated Expenses across 17 years of filings, most recently posting $34.1 million for Q1 2026.

• Accumulated Expenses for Q1 2026 came in at $34.1 million, up 34.96% year-over-year; the trailing twelve-month figure through Mar 2026 was $34.1 million (up 34.96% YoY), and the FY2025 annual result was $90.6 million, changed 0.11% from the prior year.
• Accumulated Expenses came in at $34.1 million for Q1 2026 at Corcept Therapeutics, down from $90.6 million in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $108.4 million in Q3 2025 to a low of $13.1 million in Q1 2022.
• The 5-year median for Accumulated Expenses is $32.4 million (2022), against an average of $49.5 million.
• Across the five-year window, Accumulated Expenses soared 147.54% in 2022 and sank 43.42% in 2023, its largest moves.
• Corcept Therapeutics' Accumulated Expenses stood at $30.8 million in 2022, then jumped by 67.63% to $51.6 million in 2023, then jumped by 75.68% to $90.7 million in 2024, then dropped by 0.11% to $90.6 million in 2025, then sank by 62.37% to $34.1 million in 2026.
• The last three Accumulated Expenses figures came in at $34.1 million (Q1 2026), $90.6 million (Q4 2025), and $108.4 million (Q3 2025), per Business Quant data.